The Evolving Landscape of CAD Treatment for Patients with an Indication for Revascularization
More than 15 million Americans suffer from coronary artery disease (CAD), the leading cause of mortality in the United States. According to the online journal Circulation, CAD patients who fail to modify their lifestyle and/or present poor adherence to a medication regimen aimed to control CAD risk factors often place themselves at higher risk for severe clinical events following surgery.
High-risk patients present a clinical indication for revascularization; however, patient comorbidities and coronary anatomy complexity have made the study of percutaneous coronary intervention (PCI) somewhat limited. Many high-risk CAD patients are not offered revascularization via PCI, possibly due to the extent of these patients’ comorbidities. Further advances in PCI technologies and methods have allowed complete revascularization through PCI to become an appropriate treatment option for high-risk CAD patients. Implementing strategic risk assessments with contemporary risk models before treatment is highly valuable in identifying the most appropriate patients for revascularization. These risk assessments may include a patient’s current comorbidities, coronary anatomy complexity, current ventricular function, and hemodynamic status.
To learn more about the Impella® platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: abiomed.com/important-safety-information